Hepatocellular carcinoma screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]

Overview

According to the American Association of Liver Diseases, screening for hepatocellular carcinoma by ultrasound (US) is recommended among patients with hepatitis B, hepatitis C, and cirrhosis. Screening is also recommended for Asian men over the age of 40, Asian women over the age of 50, and African American.

Screening

Screening for hepatocellular carcinoma by abdominal ultrasound and serum levels of alpha-fetoprotein is recommended for the following populations:^[1]^[2]

Patients with hepatitis B
Patients with hepatitis C
Patietns with cirrhosis
Asian men over the age of 40
Asian women over the age of 50
African American

References

↑ Trad, Dorra; Bibani, Norsaf; Sabbah, Meriam; Elloumi, Hela; Gargouri, Dalila; Ouakaa, Asma; Kharrat, Jamel (2017). “Known, new and emerging risk factors of hepatocellular carcinoma (review)”. La Presse Médicale. 46 (11): 1000–1007. doi:10.1016/j.lpm.2017.09.025. ISSN 0755-4982.
↑ Sirlin CB, Kielar AZ, Tang A, Bashir MR (2018). “LI-RADS: a glimpse into the future”. Abdom Radiol (NY). 43 (1): 231–236. doi:10.1007/s00261-017-1448-1. PMID 29318354.

Template:WikiDoc Sources

[TradBibani2017-1] Trad, Dorra; Bibani, Norsaf; Sabbah, Meriam; Elloumi, Hela; Gargouri, Dalila; Ouakaa, Asma; Kharrat, Jamel (2017). “Known, new and emerging risk factors of hepatocellular carcinoma (review)”. La Presse Médicale. 46 (11): 1000–1007. doi:10.1016/j.lpm.2017.09.025. ISSN 0755-4982.

[pmid29318354-2] Sirlin CB, Kielar AZ, Tang A, Bashir MR (2018). “LI-RADS: a glimpse into the future”. Abdom Radiol (NY). 43 (1): 231–236. doi:10.1007/s00261-017-1448-1. PMID 29318354.

[1]

[2]